CD33 and acute myeloid leukemia: Positive clinical outcomes were reported in phase I trials of 225Ac-lintuzumab, and a phase II study of 225Ac-lintuzumab monotherapy for older patients with untreated acute myeloid leukaemia is now in progress and is also being studied in a subset of patients with CD33-positive multiple myeloma [46].